Chicago—Docetaxel monotherapy after radical prostatectomy was associated with more-rapid biochemical progression of prostate cancer in some patient subgroups, such as those with a Gleason score of 7 or below, according to unexpected results from a negative Phase III study.
The study tested the hypothesis that docetaxel monotherapy after radical prostatectomy would improve biochemical disease-free survival relative to surveillance in high-risk, castrate-resistant prostate cancer, but that